BMEA

Biomea Fusion, Inc. NASDAQ Listed Apr 16, 2021

Healthcare ·Biotechnology ·US · biomeafusion.com

$1.60

After hrs $1.69 +5.41%

Mkt Cap $95.2M

52w Low $0.87 33.0% of range 52w High $3.08

50d MA $1.53 200d MA $1.53

P/E (TTM) -1.2x

EV/EBITDA -0.1x

P/B 2.4x

Debt/Equity 0.1x

ROE -209.1%

P/FCF -0.9x

RSI (14) —

ATR (14) —

Beta -0.27

50d MA $1.53

200d MA $1.53

Avg Volume 1.4M

About

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 24, 2026	AMC	-0.25	-0.64	-156.0%	1.13	+0.9%	+8.0%	+21.2%	+16.8%	+16.8%	+35.4%	—
Nov 4, 2025	AMC	-0.26	-0.27	-3.8%	1.26	-0.8%	+6.3%	+3.2%	+8.7%	+8.7%	+11.1%	—
Aug 5, 2025	AMC	-0.59	-0.51	+13.6%	1.58	+1.9%	+0.6%	+3.2%	-2.5%	-3.2%	+4.4%	—
May 5, 2025	AMC	-0.84	-0.80	+4.8%	2.00	-4.0%	-16.5%	-15.0%	-12.5%	-18.5%	-11.5%	—
Mar 31, 2025	AMC	-1.00	-0.81	+19.0%	2.13	+5.2%	-6.6%	+1.4%	-8.5%	-0.5%	-5.6%	—
Oct 29, 2024	AMC	-1.05	-0.91	+13.3%	12.06	+1.0%	-14.3%	-22.3%	-25.0%	-26.7%	-26.1%	—
Jul 31, 2024	AMC	-1.03	-1.03	+0.0%	5.57	+6.6%	+3.2%	+2.3%	+1.8%	+9.5%	+3.6%	—
May 2, 2024	AMC	-1.02	-1.09	-6.9%	11.93	+7.5%	+3.5%	+2.8%	+0.6%	-7.2%	-4.1%	—
Apr 1, 2024	AMC	-0.85	-0.98	-15.3%	15.30	-9.9%	-16.3%	-8.8%	-17.6%	-16.8%	-18.2%	—
Oct 30, 2023	AMC	-0.83	-0.80	+3.6%	11.06	-7.3%	-7.6%	-5.5%	-9.0%	-8.8%	-16.3%	—
Jul 31, 2023	AMC	-0.86	-0.70	+18.6%	22.25	+0.3%	-6.7%	-13.7%	-14.7%	-13.2%	-17.8%	—
May 2, 2023	AMC	-0.80	-0.98	-22.5%	29.00	+3.1%	+5.8%	+10.4%	+12.1%	+15.0%	+16.3%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 28	D. Boral Capital	Maintains	Buy → Buy	—	$1.73	$1.72	-0.6%	-11.6%	-15.6%	-21.4%	-20.8%	—
Apr 8	D. Boral Capital	Maintains	Buy → Buy	—	$1.90	$1.90	+0.0%	-7.4%	-2.6%	-1.6%	-1.1%	+2.6%
Mar 27	Citigroup	Maintains	Buy → Buy	—	$1.37	$1.36	-0.7%	-3.6%	-3.6%	+11.7%	+8.8%	+12.4%
Mar 25	D. Boral Capital	Maintains	Buy → Buy	—	$1.13	$1.14	+0.9%	+8.0%	+21.2%	+16.8%	+16.8%	+35.4%
Jan 13	D. Boral Capital	Maintains	Buy → Buy	—	$1.46	$1.52	+4.1%	+4.1%	+11.0%	-4.1%	-3.4%	-5.5%
Nov 10	Citigroup	Maintains	Buy → Buy	—	$1.37	$1.40	+2.2%	+0.0%	+2.2%	+0.0%	-5.8%	-6.6%
Nov 5	D. Boral Capital	Maintains	Buy → Buy	—	$1.26	$1.25	-0.8%	+6.3%	+3.2%	+8.7%	+8.7%	+11.1%
Oct 27	D. Boral Capital	Maintains	Buy → Buy	—	$1.46	$1.48	+1.4%	-2.7%	-5.5%	-6.2%	-8.9%	-6.8%
Oct 7	D. Boral Capital	Maintains	Buy → Buy	—	$2.67	$1.98	-25.8%	-30.7%	-37.1%	-33.0%	-37.1%	-38.2%
Oct 3	D. Boral Capital	Maintains	Buy → Buy	—	$2.13	$2.15	+0.9%	+0.9%	+25.4%	-13.1%	-21.1%	-16.0%
Aug 11	Citigroup	Maintains	Buy → Buy	—	$1.54	$1.55	+0.6%	-0.6%	+7.1%	+11.7%	+9.7%	+12.3%
Aug 6	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$1.58	$1.61	+1.9%	+0.6%	+3.2%	-2.5%	-3.2%	+4.4%
Aug 6	D. Boral Capital	Maintains	Buy → Buy	—	$1.58	$1.61	+1.9%	+0.6%	+3.2%	-2.5%	-3.2%	+4.4%
Jul 21	D. Boral Capital	Maintains	Buy → Buy	—	$1.85	$1.89	+2.2%	-1.1%	-1.6%	+0.0%	-2.2%	-1.1%
Jul 16	Citigroup	Maintains	Buy → Buy	—	$1.78	$1.85	+3.9%	+7.3%	+5.6%	+3.9%	+2.8%	+2.2%
Jun 24	D. Boral Capital	Maintains	Buy → Buy	—	$1.69	$1.77	+4.7%	+11.2%	+14.8%	+17.8%	+7.1%	+6.5%
Jun 18	D. Boral Capital	Maintains	Buy → Buy	—	$2.90	$2.06	-29.0%	-34.1%	-37.6%	-41.7%	-35.2%	-33.1%
Jun 13	D. Boral Capital	Maintains	Buy → Buy	—	$2.61	$2.57	-1.5%	-9.6%	+0.8%	+11.1%	-26.8%	-30.7%
May 15	D. Boral Capital	Maintains	Buy → Buy	—	$1.46	$1.46	+0.0%	-2.1%	+4.1%	+3.4%	+7.5%	-0.7%
May 6	D. Boral Capital	Maintains	Buy → Buy	—	$2.00	$1.92	-4.0%	-16.5%	-15.0%	-12.5%	-18.5%	-11.5%
May 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.00	$1.92	-4.0%	-16.5%	-15.0%	-12.5%	-18.5%	-11.5%
Apr 2	Barclays	Maintains	Equal Weight → Equal Weight	—	$1.99	$1.94	-2.5%	+8.5%	-2.0%	+6.5%	+1.0%	-14.1%
Apr 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.13	$2.24	+5.2%	-6.6%	+1.4%	-8.5%	-0.5%	-5.6%
Mar 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.30	$2.25	-2.2%	-7.4%	-13.5%	-6.1%	-15.2%	-7.8%
Mar 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.79	$2.82	+1.1%	-3.6%	-9.7%	-10.8%	-17.6%	-23.7%
Mar 24	D. Boral Capital	Maintains	Buy → Buy	—	$2.87	$3.00	+4.5%	-2.8%	-6.3%	-12.2%	-13.2%	-19.9%
Mar 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.87	$3.00	+4.5%	-2.8%	-6.3%	-12.2%	-13.2%	-19.9%
Mar 19	D. Boral Capital	Maintains	Buy → Buy	—	$2.53	$2.55	+0.8%	+7.9%	+9.5%	+13.4%	+10.3%	+6.3%
Jan 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.06	$4.17	+2.7%	+0.0%	-2.0%	+4.7%	+6.4%	+10.3%
Jan 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.15	$4.15	+0.0%	+0.0%	-2.2%	-2.2%	-4.1%	+2.4%
Jan 13	D. Boral Capital	Maintains	Buy → Buy	—	$3.98	$3.84	-3.5%	+4.3%	+4.3%	+2.0%	+2.0%	+0.0%
Jan 10	D. Boral Capital	Maintains	Buy → Buy	—	$4.27	$4.21	-1.4%	-6.8%	-2.8%	-2.8%	-4.9%	-4.9%
Dec 19	D. Boral Capital	Maintains	Buy → Buy	—	$3.88	$4.02	+3.6%	+5.2%	+9.0%	+3.9%	+3.4%	+5.2%
Dec 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.64	$4.62	-0.4%	-16.4%	-12.1%	-8.8%	-13.1%	-13.6%
Dec 17	D. Boral Capital	Maintains	Buy → Buy	—	$5.85	$5.21	-10.9%	-20.7%	-33.7%	-30.3%	-27.7%	-31.1%
Dec 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.64	$5.69	+0.9%	+3.7%	-17.7%	-31.2%	-27.7%	-25.0%
Dec 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.79	$5.85	+1.0%	-0.5%	+6.0%	+0.2%	-2.6%	+1.0%
Dec 10	D. Boral Capital	Maintains	Buy → Buy	—	$5.79	$5.85	+1.0%	-0.5%	+6.0%	+0.2%	-2.6%	+1.0%
Nov 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.28	$6.28	+0.0%	+1.6%	+2.5%	+10.4%	+9.7%	+11.8%
Nov 19	D. Boral Capital	Maintains	Buy → Buy	—	$6.43	$6.45	+0.3%	-0.2%	-2.3%	-0.8%	+0.2%	+7.8%
Oct 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.34	$10.46	+1.2%	-9.4%	-12.6%	-14.5%	-13.8%	-14.1%
Oct 31	Piper Sandler	Maintains	Overweight → Overweight	—	$10.34	$10.46	+1.2%	-9.4%	-12.6%	-14.5%	-13.8%	-14.1%
Oct 31	EF Hutton	Maintains	Buy → Buy	—	$10.34	$10.46	+1.2%	-9.4%	-12.6%	-14.5%	-13.8%	-14.1%
Oct 30	Barclays	Maintains	Equal Weight → Equal Weight	—	$12.06	$12.18	+1.0%	-14.3%	-22.3%	-25.0%	-26.7%	-26.1%
Oct 30	EF Hutton	Maintains	Buy → Buy	—	$12.06	$12.18	+1.0%	-14.3%	-22.3%	-25.0%	-26.7%	-26.1%
Oct 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.24	$11.25	+0.1%	+2.0%	+0.6%	+2.8%	+8.1%	+10.4%
Oct 22	HC Wainwright& Co.	Maintains	Buy → Buy	—	$11.24	$11.25	+0.1%	+2.0%	+0.6%	+2.8%	+8.1%	+10.4%
Sep 27	Truist	Upgrade	Hold → Buy	—	$9.57	$11.48	+20.0%	+3.4%	+5.5%	-0.7%	+5.9%	+5.4%
Sep 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.57	$11.48	+20.0%	+3.4%	+5.5%	-0.7%	+5.9%	+5.4%
Sep 27	Barclays	Maintains	Equal Weight → Equal Weight	—	$9.57	$11.48	+20.0%	+3.4%	+5.5%	-0.7%	+5.9%	+5.4%

Recent Filings

8-K · 7.01 ! Medium

Biomea Fusion, Inc. -- 8-K 7.01: Regulation FD Disclosure

Biomea Fusion furnished investor presentation slides for an upcoming call, signaling management intends to communicate updates on company strategy or performance directly to shareholders.

Apr 28

8-K

Unknown — 8-K Filing

Biomea's lead diabetes drug showed sustained benefits months after short treatment, potentially supporting a valuable therapeutic approach that could drive near-term clinical advancement and investor confidence.

Mar 24

8-K · 7.01 ! Medium

Biomea Fusion, Inc. -- 8-K 7.01: Regulation FD Disclosure

Biomea Fusion disclosed a corporate presentation to investors via their website, providing updated company information for stakeholder review.

Feb 25

Data updated apr 24, 2026 10:09pm · Source: massive.com